Our Pipeline

Utilizing Our Proprietary Technologies to Create Life-Changing Therapies

Internal Development Programs

Program Indication Preclinical Phase 1 Phase 2 Phase 3 Next Catalyst
XCART™ Platform B-Cell Non-Hodgkin Lymphoma
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
Phase 3 Phase not started
  • 5/2020: Research and Development Collaboration: Scripps Research

Upcoming

  • 2020: FDA INTERACT Meeting
  • 2020: Secure additional academic and development collaborations
  • 2021: Expected IND Filing
  • Goal to secure industry collaboration

PolyXen - Partnered Drug Delivery Programs

Program Indication Preclinical Phase 1 Phase 2 Phase 3 Partners
PolyXen® Next Generation Delivery Platform for Biologics Takeda

Active Partnership with Takeda (receiving royalties under license agreement)